Cholesterol-lowering drugs: Focus on Ezetimibe

Cholesterol-lowering drugs: Focus on ezetimibe

Harold E. Bays
Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA

Abstract

Ezetimibe is an intestinal cholesterol/sterol inhibitor. It is generally well-tolerated, and except for coadministration with cyclosporin (which increases concentration of both ezetimibe and cyclosporin), has limited drug interactions. Clinical trial data suggests that ezetimibe 10 mg orally once a day reduces low density lipoprotein cholesterol (LDL-C) levels about 15-25% as monotherapy or when added to statins, depending on the patient and individual clinical trial. Ezetimibe also reduces lipoprotein remnants. Due to its additive effects to statins, international lipid guidelines recommend ezetimibe as an option for patients who do not achieve LDL-C treatment goals with statins alone. The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial demonstrated that when added to statin therapy, ezetimibe incrementally lowered LDL-C levels and modestly improved cardiovascular outcomes. Ezetimibe is formulated as monotherapy, or as a fixed-dose combination with statins or bempedoic acid. Finally, ezetimibe is the only pharmacotherapy approved for treatment of beta-sitosterolemia, which is a rare autsomal recessive disorder resulting in enhanced intestinal cholesterol absorption, increased circulating sterols, and tendinous and cutaneous xanthomas, arthritis or arthralgia, and premature cardiovascular disease.

References

  1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111-88. https://doi.org/10.1093/eurheartj/ehz455
  2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 73:e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003
  3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:3168-209. https://doi.org/10.1016/j.jacc.2018.11.002
  4. Descamps O, Tomassini JE, Lin J, et al. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis 2015; 240:482-9. https://doi.org/10.1016/j.atherosclerosis.2015.03.004
  5. Descamps OS, De Sutter J, Guillaume M, Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis 2011; 217:308-21. https://doi.org/10.1016/j.atherosclerosis.2011.06.010
  6. Miettinen TA, Strandberg TE, Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000; 20:1340-6. https://doi.org/10.1161/01.atv.20.5.1340
  7. Stellaard F, von Bergmann K, Sudhop T, Lütjohann D. The value of surrogate markers to monitor cholesterol absorption, synthesis and bioconversion to bile acids under lipid lowering therapies. J Steroid Biochem Mol Biol 2017; 169:111-22. https://doi.org/10.1016/j.jsbmb.2016.03.030
  8. Wu WF, Wang QH, Zhang T, et al. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease. Clin Biochem 2013; 46:993-8. https://doi.org/10.1016/j.clinbiochem.2013.04.003
  9. Masuda D, Yamashita S. Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis. Journal of atherosclerosis and thrombosis 2017; 24:120-2. https://doi.org/10.5551/jat.ED065
  10. Lin X, Racette SB, Ma L, et al. Ezetimibe Increases Endogenous Cholesterol Excretion in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2017; 37:990-6. https://doi.org/doi:10.1161/ATVBAHA.117.309119
  11. Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annual review of physiology 2011; 73:239-59. https://doi.org/10.1146/annurev-physiol-012110-142233
  12. Stitziel NO, MacRae CA. A clinical approach to inherited premature coronary artery disease. Circ Cardiovasc Genet 2014; 7:558-64. https://doi.org/10.1161/CIRCGENETICS.113.000152
  13. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007; 117:1968-78. https://doi.org/10.1172/JCI30060
  14. Lauridsen BK, Stender S, Frikke-Schmidt R, et al. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J 2015; 36:1601-8. https://doi.org/10.1093/eurheartj/ehv108
  15. Zhan S, Tang M, Liu F, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev 2018; 11:CD012502. https://doi.org/10.1002/14651858.CD012502.pub2
  16. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44:467-94. https://doi.org/10.2165/00003088-200544050-00002
  17. Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb 2017; 24:95-109. https://doi.org/10.5551/jat.RV16003
  18. Toth PP, Bays HE, Brown WV, et al. Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. J Clin Lipidol 2019; 13:997-1007.e8. https://doi.org/10.1016/j.jacl.2019.09.001
  19. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002; 11:1587-604. https://doi.org/10.1517/13543784.11.11.1587
  20. Ambegaonkar BM, Tipping D, Polis AB, et al. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis 2014; 237:829-37. https://doi.org/10.1016/j.atherosclerosis.2014.10.105
  21. Lorenzi M, Ambegaonkar B, Baxter CA, et al. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clin Res Cardiol 2019; 108:487-509. https://doi.org/10.1007/s00392-018-1379-z
  22. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387-97. https://doi.org/10.1056/NEJMoa1410489
  23. Bays HE, Patel MD, Mavros P, et al. Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. J Clin Lipidol 2017; 11:929-37. https://doi.org/10.1016/j.jacl.2017.04.121
  24. Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol 2017; 2:547-55. https://doi.org/10.1001/jamacardio.2017.0083
  25. Oyama K, Giugliano RP, Blazing MA, et al. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol 2021; 78:1499-507. https://doi.org/10.1016/j.jacc.2021.08.011
  26. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015; 65:1552-61. https://doi.org/10.1016/j.jacc.2015.02.020
  27. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107:2409-15. https://doi.org/10.1161/01.CIR.0000068312.21969.C8
  28. Bays HE, Averna M, Majul C, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol 2013; 112:1885-95. https://doi.org/10.1016/j.amjcard.2013.08.031
  29. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148:447-55. https://doi.org/10.1016/j.ahj.2004.03.052
  30. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010; 12:210-8. https://doi.org/10.1111/j.1463-1326.2009.01152.x
  31. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102:1495-501. https://doi.org/10.1016/j.amjcard.2008.09.076
  32. Ai C, Zhang S, He Q, Shi J. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids Health Dis 2018; 17:239. https://doi.org/10.1186/s12944-018-0880-8
  33. Tsujita K, Sugiyama S, Sumida H, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015; 66:495-507. https://doi.org/10.1016/j.jacc.2015.05.065
  34. Tsujita K, Yamanaga K, Komura N, et al. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial. Eur J Prev Cardiol 2016; 23:1524-8. https://doi.org/10.1177/2047487316655465
  35. Tsujita K, Yamanaga K, Komura N, et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. Atherosclerosis 2016; 251:367-72. https://doi.org/10.1016/j.atherosclerosis.2016.05.025
  36. Fujisue K, Nagamatsu S, Shimomura H, et al. Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial. Int J Cardiol 2018; 268:23-6. https://doi.org/10.1016/j.ijcard.2018.04.051
  37. Oh PC, Jang AY, Ha K, et al. Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. Am J Cardiol 2021; 154:22-8. https://doi.org/10.1016/j.amjcard.2021.05.039
  38. Sahebkar A, Kiaie N, Gorabi AM, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res 2021; 84:101127. https://doi.org/10.1016/j.plipres.2021.101127
  39. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54:293-302. https://doi.org/10.1016/j.jacc.2009.04.033
  40. Sakamoto K, Kawamura M, Kohro T, et al. Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins. PLoS One 2015; 10:e0138332. https://doi.org/10.1371/journal.pone.0138332
  41. Watanabe E, Yamaguchi J, Arashi H, et al. Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome. J Lipids 2015; 2015:109158. https://doi.org/10.1155/2015/109158
  42. Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017; 38:2264-76. https://doi.org/10.1093/eurheartj/ehx162
  43. Im J, Kawada-Watanabe E, Yamaguchi J, et al. Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naive acute coronary syndrome. Sci Rep 2021; 11:7480. https://doi.org/10.1038/s41598-021-87098-x
  44. Cortese F, Gesualdo M, Cortese A, et al. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacol Res 2016; 107:1-18. https://doi.org/10.1016/j.phrs.2016.02.012
  45. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152-60. https://doi.org/10.1016/s0002-9149(03)00530-7
  46. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99:673-80. https://doi.org/10.1016/j.amjcard.2006.10.022
  47. Kim KJ, Kim SH, Yoon YW, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther 2016; 34:371-82. https://doi.org/10.1111/1755-5922.12213
  48. Hong SJ, Jeong HS, Ahn JC, et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clin Ther 2018; 40:226-41 e4. https://doi.org/10.1016/j.clinthera.2017.12.018
  49. Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 2015; 56:278-85. https://doi.org/10.1536/ihj.14-311
  50. Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol 2011; 108:523-30. https://doi.org/10.1016/j.amjcard.2011.03.079
  51. Torimoto K, Okada Y, Mori H, et al. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis 2013; 12:137. https://doi.org/10.1186/1476-511X-12-137
  52. Lee J, Hwang YC, Lee WJ, et al. Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study. Diabetes Ther 2020; 11:859-71. https://doi.org/10.1007/s13300-020-00778-1
  53. Yamazaki D, Ishida M, Watanabe H, et al. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis 2013; 12:9. https://doi.org/10.1186/1476-511X-12-9
  54. Oh M, Kim H, Shin EW, et al. Comparison of High-Dose Rosuvastatin Versus Low-Dose Rosuvastatin Plus Ezetimibe on Carotid Atherosclerotic Plaque Inflammation in Patients with Acute Coronary Syndrome. J Cardiovasc Transl Res 2020; 13:900-7. https://doi.org/10.1007/s12265-020-10009-4
  55. Lee SA, Kim W, Hong TJ, et al. Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study. Clin Ther 2021; 43:1573-89. https://doi.org/10.1016/j.clinthera.2021.07.016
  56. Yang YJ, Lee SH, Kim BS, et al. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Clin Ther 2017; 39:107-17. https://doi.org/10.1016/j.clinthera.2016.11.014
  57. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149:464-73. https://doi.org/10.1016/j.ahj.2004.11.023
  58. Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis 2014; 232:86-93. https://doi.org/10.1016/j.atherosclerosis.2013.10.022
  59. Oh M, Kim H, Shin EW, et al. Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation. Medicine (Baltimore) 2021; 100:e25114. https://doi.org/10.1097/MD.0000000000025114
  60. Yu M, Liang C, Kong Q, et al. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis 2020; 19:1. https://doi.org/10.1186/s12944-019-1182-5
  61. Lee J, Lee SH, Kim H, et al. Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence. J Clin Pharm Ther 2021; 46:134-42. https://doi.org/10.1111/jcpt.13271
  62. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308:2497-506. https://doi.org/10.1001/jama.2012.25790
  63. Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. Cardiol Rev 2019; 27:49-56. https://doi.org/10.1097/CRD.0000000000000218
  64. Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 2016; 10:556-67. https://doi.org/10.1016/j.jacl.2015.12.025
  65. Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis 2018; 277:195-203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002
  66. Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020; 27:593-603. https://doi.org/10.1177/2047487319864671
  67. Bastida JM, Giros ML, Benito R, et al. Sitosterolemia: Diagnosis, Metabolic and Hematological Abnormalities, Cardiovascular Disease and Management. Curr Med Chem 2019; 26:6766-75. https://doi.org/10.2174/0929867325666180705145900
  68. Tada H, Nomura A, Ogura M, et al. Diagnosis and Management of Sitosterolemia 2021. J Atheroscler Thromb 2021; 28:791-801. https://doi.org/10.5551/jat.RV17052
  69. Kirkpatrick CF, Bolick JP, Kris-Etherton PM, et al. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. J Clin Lipidol 2019; 13:689-711 e1. https://doi.org/10.1016/j.jacl.2019.08.003
  70. Buren J, Ericsson M, Damasceno NRT, Sjodin A. A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial. Nutrients 2021; 13:814. https://doi.org/10.3390/nu13030814
  71. Azevedo de Lima P, Baldini Prudencio M, Murakami DK, et al. Effect of classic ketogenic diet treatment on lipoprotein subfractions in children and adolescents with refractory epilepsy. Nutrition 2017; 33:271-7. https://doi.org/10.1016/j.nut.2016.06.016
  72. Kwiterovich PO, Jr., Vining EP, Pyzik P, et al. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 2003; 290:912-20. https://doi.org/10.1001/jama.290.7.912
  73. Goldberg IJ, Ibrahim N, Bredefeld C, et al. Ketogenic diets, not for everyone. J Clin Lipidol 2021; 15:61-7. https://doi.org/10.1016/j.jacl.2020.10.005
  74. Schaffer AE, D'Alessio DA, Guyton JR. Extreme elevations of low-density lipoprotein cholesterol with very low carbohydrate, high fat diets. J Clin Lipidol 2021; 15:525-6. https://doi.org/10.1016/j.jacl.2021.04.010
  75. Bays HE, McCarthy W, Burridge K, Tondt J, Karjoo S, Christensen S, Ng J, Golden A, Davisson L, Richardson L. Obesity Algorithm eBook, presented by the Obesity Medicine Association. www.obesityalgorithm.org. 2021. https://obesitymedicine.org/obesity-algorithm/ (Accessed = September 18, 2021).

Send mail to Author


Send Cancel

Custom technologies based on your needs

  • MongoDB
  • ElasticSearch
  • Redis
  • Solr
  • Memcached